Pip: Welcome to Pall MED Prep — where the clinical questions are rarely tidy and the evidence is almost always more complicated than the guideline implies.

Mara: Today we’re covering two areas: what a new systematic review actually tells us about opioids for acute breathlessness, and the diagnostic and pain management puzzle that follows a Whipple’s procedure. All of it comes from Dr. Rahul D Arora, the editor and founder of this blog, who is currently working as a consultant in the private sector in India. Let’s start with the breathlessness evidence.

Opioids and Acute Breathlessness: What the Evidence Actually Shows

Pip: The premise sounds straightforward — opioids for breathlessness, a well-worn palliative tool. But a new systematic review by Haubner and colleagues puts that confidence under some pressure.

Mara: The post frames the review’s scope precisely: it targets “fast acting drugs with site of action within the Central Nervous System for spontaneous breathlessness with responses measured with the time frame of less than 20 minutes.”

Pip: So the upshot is that this isn’t about long-term opioid titration — it’s asking whether these drugs can act like rescue inhalers, and the answer turns out to be mostly no.

Mara: Most opioid formulations showed no benefit over placebo. The two exceptions were parenteral morphine studies, but even those came with safety signals — more intubations in acute respiratory failure and more cardiovascular events in acute pulmonary edema. Benzodiazepines fared no better overall.

Pip: Real-world evidence, still wanting. The science has a rationale; the trials haven’t caught up — and apparently the trials are also quite small.

Mara: Predominantly small crossover studies in advanced cancer or COPD, with significant heterogeneity in setting, comparator, and route. The review lands on supporting non-pharmacological management over parenteral opioids for now, pending better evidence.

Pip: Which brings us to a harder question — when opioids are already on board and pain is the problem, not breathlessness.

Pain After a Whipple’s: When the Diagnosis Is Still Uncertain

Pip: The post-Whipple scenario asks something genuinely difficult: how do you characterize and treat cancer-related pain when histopathological confirmation of recurrence hasn’t arrived yet?

Mara: The post lays out the differential clearly: “recurrent disease, neuropathic pain syndrome, pancreatitis in the remnant, visceral hypersensitivity and psychological distress” — and notably adds that central and peripheral sensitization remain possible even without tumor recurrence.

Pip: That last point matters. Previous surgery, chronic inflammation, and repetitive nociceptive signaling can remodel pain pathways independently of what a scan shows.

Mara: The post gives clinical handles for coeliac plexus involvement specifically — epigastric pain radiating to the back, worsening after meals, only partial opioid response pointing toward a neuropathic or sympathetically maintained component.

Pip: And then there’s the lymph node question, which the title flags directly: does size matter?

Mara: The answer is carefully hedged. A one-to-two centimeter node near the coeliac plexus can cause pain through direct neural infiltration, nerve compression, local inflammation, or perineural spread. A sub-centimetric node, the post argues, doesn’t naturally earn the label of pain generator and shifts the weight toward alternative diagnoses.

Pip: So the node’s address matters as much as its size — proximity to neural tissue doing a lot of work there.

Mara: And the intervention question is equally unsettled. Coeliac plexus neurolysis in the absence of confirmed recurrence, in a post-operative field with possible anatomical distortion, is a genuinely difficult call. The post notes that efficacy data for the procedure comes from the pancreatic cancer population — not the post-Whipple setting specifically.

Pip: Which means the clinician is being asked to extrapolate across a surgical boundary that changes the anatomy and probably the procedure’s success rate.

Mara: The post closes on clinico-radiological correlation — FDG avidity, tumor markers, CT findings alongside the clinical picture — as the path through. No single feature is sufficient on its own.

---

Pip: Two posts, one consistent thread — the evidence base keeps arriving with asterisks attached.

Mara: Whether it’s opioids for breathlessness or pain management after complex surgery, the clinical judgment of the specialist remains the operative variable. More in the next episode.